<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03104036</url>
  </required_header>
  <id_info>
    <org_study_id>F16-27449A</org_study_id>
    <nct_id>NCT03104036</nct_id>
  </id_info>
  <brief_title>Faecal Bacteriotherapy for Ulcerative Colitis</brief_title>
  <acronym>FACTU</acronym>
  <official_title>Faecal Bacteriotherapy for Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute for Clinical and Experimental Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institute of Animal Physiology and Genetics Academy of Science Czech Republic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute for Clinical and Experimental Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The etiopathogenesis of ulcerative colitis (UC) is not fully understood. One of the theories
      of UC pathogenesis represents a pathological response of mucosal immunity to intestinal
      microbiota. Potential therapeutic procedure how to affect this fact is the faecal microbiota
      transplantation (FMT). Review of the literature on FMT suggests great potential as the
      treatment for UC, but two prospective controlled study that has been published yet are
      inconsistent.

      The first objective of the project is to compare the administration of FMT enema with
      mesalazine enema for inducing remission in patients with active left-sided UC in the form of
      a prospective, randomized, controlled study. The second objective is to observe changes in
      the intestinal microbiota during and after FMT focusing on bacterial DNA sequencing to
      identify the bacterial species which are responsible for the effect of the FMT.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 19, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be split into two branches of the study by randomization criteria (gender, imunosupresive therapy). Each branch of the study will have 25-30 patients. The first group will be treated with 4 g mesalazine enema 1x daily for 2 weeks, then every other day until the end of the 6th week. A second group of patients will be applied enema prepared from 50 g of stool of examined donor dissolved in 150 ml of normal saline, the 1st week 5 times, than one time a week until the end of the 6th week.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical remission</measure>
    <time_frame>Week 12</time_frame>
    <description>Mayo score ≤ 2 with no subscore &gt; 1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endoscopic remission</measure>
    <time_frame>Week 6 and 12</time_frame>
    <description>Mayo endoscopic score = 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response</measure>
    <time_frame>Week 6 and 12</time_frame>
    <description>Decrease of Mayo score ≥ 2</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Mesalazine enema</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Will be treated with 4 g mesalazine enema 1x daily for 2 weeks, then every other day until the end of the 6th week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Faecal bacterial transplantation enema</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will be applied enema prepared from 50 g of stool of examined donor dissolved in 150 ml of normal saline, the 1st week 5 times, than one time a week until the end of the 6th week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Faecal bacterial transplantation</intervention_name>
    <description>Enema prepared from 50 g of stool of examined donor dissolved in 150 ml of normal saline</description>
    <arm_group_label>Faecal bacterial transplantation enema</arm_group_label>
    <other_name>FMT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesalazine 4G Enema</intervention_name>
    <description>Standard mesalazine enema</description>
    <arm_group_label>Mesalazine enema</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Left-sided ulcerative colitis &gt; 15cm ongoing more than 3 month

          -  Mayo score &lt; 10

          -  Endoscopic Mayo score ≥ 2

        Exclusion Criteria:

          -  Anti-TNF medication in the previous 6 months

          -  Cyclosporine in the previous 4 weeks

          -  Methotrexate in the previous 2 months

          -  Prednisone &gt; 10mg

          -  The real risk of colectomy in the near future

          -  Positive stool culture (Salmonella, Shigella, Yersinia, Campylobacter, pathogenic E.
             coli)

          -  CMV infection

          -  Pregnancy, breastfeeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jan Brezina, M.D.</last_name>
    <phone>00420739602520</phone>
    <email>jan.brezina@ikem.cz</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gastroenterology departement Hospital České Budějovice</name>
      <address>
        <city>Ceske Budejovice</city>
        <state>Jihočeský Kraj</state>
        <zip>370 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Shonová, M.D.</last_name>
      <email>shonova@nemcb.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum péče o zažívací trakt Vítkovická nemocnice</name>
      <address>
        <city>Ostrava - Vitkovice</city>
        <state>Moravskoslezský Kraj</state>
        <zip>703 84</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbora Pipek, M.D.</last_name>
      <email>barbora.pipek@seznam.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Second department of internal medicine of University Hospital Olomouc</name>
      <address>
        <city>Olomouc</city>
        <state>Olomoucký Kraj</state>
        <zip>77900</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michal Konečný, M.D.</last_name>
      <email>michal.konecny@fnol.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IV. Department of Internal Medicine, General University Hospital in Prague</name>
      <address>
        <city>Prague</city>
        <state>Prague 2</state>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pavel Hrabák, M.D.</last_name>
      <email>pavel.hrabak@vfn.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Internal departement of Thomayer Hospital</name>
      <address>
        <city>Prague</city>
        <state>Prague 4</state>
        <zip>14059</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiří Vejmelka, M.D.</last_name>
      <email>jiri.vejmelka@ftn.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ISCARE</name>
      <address>
        <city>Prague</city>
        <state>Prague 7</state>
        <zip>17004</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Bortlík, M.D.</last_name>
      <email>mbortlik@seznam.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>II. Department of Internal Medicine University Hospital Vinohrady</name>
      <address>
        <city>Prague</city>
        <zip>100 34</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivana Cibulková, M.D.</last_name>
      <email>ivana.cibulkova@fnkv.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of clinical and experimental medicine</name>
      <address>
        <city>Prague</city>
        <zip>14021</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Brezina, M.D.</last_name>
      <phone>00420739602520</phone>
      <email>jan.brezina@ikem.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Internal departement Hospital Na Bulovce</name>
      <address>
        <city>Prague</city>
        <zip>150 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karel Mareš, M.D.</last_name>
      <email>karel.mares@homolka.cz</email>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2017</study_first_submitted>
  <study_first_submitted_qc>March 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2017</study_first_posted>
  <last_update_submitted>March 13, 2018</last_update_submitted>
  <last_update_submitted_qc>March 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute for Clinical and Experimental Medicine</investigator_affiliation>
    <investigator_full_name>Jan Březina</investigator_full_name>
    <investigator_title>MUDr. (principal investigator)</investigator_title>
  </responsible_party>
  <keyword>Feacal bacterial transplantation</keyword>
  <keyword>Left-sided ulcerative colitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesalamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

